|
1.
|
|
12 p, 998.2 KB |
Impact of a system to assist in clinical decision-making in primary healthcare in Catalonia : prescription Self Audit
/
Pons Mesquida, M. Àngels (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Oms Arias, Míriam (Institut Català de la Salut. Unitat de Coordinació i Estratègia del Medicament) ;
Figueras, Albert 1961- (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Diogène Fadini, Eduard (Hospital Universitari Vall d'Hebron)
In 2008, in the context of a complete computerisation of medical records, the Institut Català de la Salut (ICS, Catalan Health Institute) implemented a system in its electronic clinical workstation (ECW) to assist decision-making at the prescription level. [...]
2022 -  10.1186/s12911-022-01809-6
BMC Medical Informatics and Decision Making, Vol. 22 (march 2022)
|
|
|
2.
|
|
10 p, 253.6 KB |
Spontaneously reported adverse drug reactions and their description in hospital discharge reports : a retrospective study
/
Aguilera, Cristina (Hospital Universitari Vall d'Hebron) ;
Agustí Escasany, M. Antònia (Hospital Universitari Vall d'Hebron) ;
Pérez, Eulàlia (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Gracia, Rosa Maria (Hospital Universitari Vall d'Hebron) ;
Diogène Fadini, Eduard (Hospital Universitari Vall d'Hebron) ;
Danés Carreras, Immaculada (Hospital Universitari Vall d'Hebron)
The inclusion of spontaneously reported adverse drug reactions (ADRs) in hospital discharge reports was examined, in addition to the factors associated with their inclusion, the resulting therapeutic decisions, and any recommendations made upon patient discharge regarding the suspected offending drugs. [...]
2021 - 10.3390/jcm10153293
Journal of clinical medicine, Vol. 10 Núm. 15 (january 2021) , p. 3293
|
|
|
3.
|
|
14 p, 1.2 MB |
Safer prescription of drugs : impact of the PREFASEG system to aid clinical decision-making in primary care in Catalonia
/
Pons-Mesquida, M. Àngels (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Oms-Arias, Míriam (Institut Català de la Salut. Unitat de Coordinació i Estratègia del Medicament) ;
Diogène Fadini, Eduard (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Figueras, Albert 1961- (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
In 2008, the Institut Català de la Salut (ICS, Catalan Health Institute) implemented a prescription decision support system in its electronic clinical workstation (ECW), which automatically generates online alerts for general practitioners when a possible medication-related problem (MRP) is detected. [...]
2021 - 10.1186/s12911-021-01710-8
BMC Medical Informatics and Decision Making, Vol. 21 (december 2021)
|
|
|
4.
|
|
13 p, 1.0 MB |
Adaptive Pathways : Possible Next Steps for Payers in Preparation for Their Potential Implementation
/
Vella Bonanno, Patricia (Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde) ;
Ermisch, Michael (Pharmaceutical Department, National Association of Statutory Health Insurance Funds) ;
Godman, Brian (Karolinska Institutet (Estocolm, Suècia). Division of Clinical Pharmacology) ;
Martin, Antony P. (Health Economics Centre, University of Liverpool Management School) ;
Van Den Bergh, Jesper (Department of Health) ;
Bezmelnitsyna, Liudmila (National Research Institution for Public Health) ;
Bucsics, Anna (Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA)) ;
Arickx, Francis (Department of Pharmaceutical Policy, National Institute for Health and Disability Insurance) ;
Bybau, Alexander (Zilveren Kruis Achmea) ;
Bochenek, Tomasz (Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College) ;
van de Casteele, Marc (Department of Pharmaceutical Policy, National Institute for Health and Disability Insurance) ;
Diogène Fadini, Eduard (Hospital Universitari Vall d'Hebron) ;
Eriksson, Irene (Karolinska Institutet (Estocolm, Suècia). Department of Medicine Solna) ;
Fürst, Jurij (Medicinal Products Department, Health Insurance Institute of Slovenia) ;
Gad, Mohamed (Global Health and Development Group, Imperial College) ;
Greičiūtė-Kuprijanov, Ieva (Department of Pharmacy, Ministry of Health of the Republic of Lithuania) ;
van der Graaff, Martin (National Health Care Institute (ZIN)) ;
Gulbinovič, Jolanta (State Medicines Control Agency) ;
Jones, Jan (Scottish Medicines Consortium) ;
Joppi, Roberta (Clinical Research and Drug Assessment Unit) ;
Kalaba, Marija (Pediatric Cardiology, Primary Healthcare Centre "Zemun") ;
Laius, Ott (Department of Post-authorisation Safety, State Agency of Medicines) ;
Langner, Irene (Wissenschaftliches Institut der AOK) ;
Mardare, Ileana (Faculty of Medicine, Public Health and Management Department, "Carol Davila" University of Medicine and Pharmacy Bucharest) ;
Markovic-Pekovic, Vanda (Department of Social Pharmacy, Medical Faculty, University of Banja Luka) ;
Magnusson, Einar (Department of Health Services, Ministry of Health) ;
Melien, Oyvind (Norwegian Directorate for Health) ;
Meshkov, Dmitry O. (Department of Health) ;
Petrova, Guenka I. (Department of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University of Sofia) ;
Selke, Gisbert (Wissenschaftliches Institut der AOK) ;
Sermet, Catherine (Institut de Recherche et Documentation en Economie de la Santé (IRDES)) ;
Simoens, Steven (KU Leuven Department of Pharmaceutical and Pharmacological Sciences) ;
Schuurman, Ad (National Health Care Institute (ZIN)) ;
Ramos, Ricardo (Health Technology Assessment, Pricing and Reimbursement Department, Central Administration of the Health System, National Authority of Medicines and Health Products (I.P., INFARMED)) ;
Rodrigues, Jorge (Health Technology Assessment, Pricing and Reimbursement Department, Central Administration of the Health System, National Authority of Medicines and Health Products (I.P., INFARMED)) ;
Zara, Corinne (Servei Català de la Salut) ;
Zebedin-Brandl, Eva (Main Association of Austrian Social Insurance Institutions. Department of Pharmaceutical Affairs) ;
Haycox, Alan (Health Economics Centre, University of Liverpool Management School) ;
Universitat Autònoma de Barcelona
Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The "introduction" of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. [...]
2017 - 10.3389/fphar.2017.00497
Frontiers in Pharmacology, Vol. 8 (august 2017)
|
|
|
5.
|
|
11 p, 1.4 MB |
Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation : phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database
/
Giner-Soriano, Maria (Universitat Autònoma de Barcelona) ;
Vedia Urgell, Cristina (Universitat Autònoma de Barcelona) ;
Roso-Llorach, Albert (Universitat Autònoma de Barcelona) ;
Morros, Rosa (Universitat Autònoma de Barcelona) ;
Capellà, Dolors (Universitat de Girona. Departament de Ciències Mèdiques) ;
Castells, Xavier (Universitat de Girona. Departament de Ciències Mèdiques) ;
Ferreira-Gonzalez, Ignacio (Hospital Universitari Vall d'Hebron) ;
Troncoso Mariño, Amelia (Hospital Universitari Vall d'Hebron) ;
Diogène Fadini, Eduard (Hospital Universitari Vall d'Hebron) ;
Elorza, Josep Mª (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ;
Casajuana Closas, Marc (Universitat Autònoma de Barcelona) ;
Bolíbar, Bonaventura (Universitat Autònoma de Barcelona) ;
Violán, Concepció (Universitat Autònoma de Barcelona)
Atrial fibrillation is the most common arrhythmia. Its management aims to reduce symptoms and to prevent complications through rate and rhythm control, management of concomitant cardiac diseases and prevention of related complications, mainly stroke. [...]
2016 - 10.1136/bmjopen-2015-010144
BMJ open, Vol. 6, issue 1 (Jan. 2016) , art. e010144
|
|
|
6.
|
|
11 p, 1.1 MB |
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs
/
Godman, Brian (University of Strathclyde) ;
Malmström, Rickard E. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Diogène Fadini, Eduard (Hospital Universitari Vall d'Hebron) ;
Jayathissa, Sisira (Hutt Valley DHB. Department of Medicine) ;
McTaggart, Stuart (NHS National Services Scotland) ;
Cars, Thomas (Uppsala University. Department of Medical Sciences) ;
Alvarez-Madrazo, Samantha (University of Strathclyde) ;
Baumgärtel, Christoph (Austrian Medicines and Medical Devices Agency) ;
Brzezinska, Anna (Agency for Health Technology Assessment) ;
Bucsics, Anna (Hauptverband der Österreichischen Sozialversicherungsträger) ;
Campbell, Stephen (University of Manchester. Centre for Primary Care) ;
Eriksson, Irene (Stockholm County Council. Department of Healthcare Development) ;
Finlayson, Alexander (University of Oxford. Green Templeton College) ;
Fürst, Jurij (Health Insurance Institute) ;
Garuoliene, Kristina (National Health Insurance Fund) ;
Gutiérrez-Ibarluzea, Iñaki (Osasun Saila. Ezagutu Osteba arloa) ;
Hviding, Krystyna (Norwegian Medicines Agency) ;
Herholz, Harald (Kassenärztliche Vereinigung Hessen) ;
Joppi, Roberta (Azienda Sanitaria Locale of Verona. Pharmaceutical Drug Department) ;
Kalaba, Marija (Republic Institute for Health. Department of Medicines and Pharmacoeconomics) ;
Laius, Ott (State Agency of Medicines) ;
Malinowska, Kamila (National Health Fund. Drug Management Department) ;
Pedersen, Hanne B. (Division of Health Systems and Public Health, Health Technologies and Pharmaceuticals, WHO Regional Office for Europe) ;
Markovic-Pekovic, Vanda (Ministry of Health and Social Welfare) ;
Piessnegger, Jutta (Hauptverband der Österreichischen Sozialversicherungsträger) ;
Selke, Gisbert (Wissenschaftliches Institut der AOK (WidO)) ;
Sermet, Catherine (IRDES) ;
Spillane, Susan (Trinity College. Department of Pharmacology and Therapeutics) ;
Tomek, Dominik (Slovak Medical University. Faculty of Pharmacy) ;
Vončina, Luka (Ministry of Health) ;
Vlahović-Palčevski, Vera (University Hospital Rijeka. Unit for Clinical Pharmacology) ;
Wale, Janet (Independent Consumer Advocate, VIC) ;
Wladysiuk, Magdalena (HTA Consulting) ;
van Woerkom, Menno (Dutch Institute for Rational Use of Medicine) ;
Zara, Corinne (Institut Català de la Salut) ;
Gustafsson, Lars L. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Universitat Autònoma de Barcelona
Background : There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. [...]
2014 - 10.3389/fphar.2014.00109
Frontiers in Pharmacology, Vol. 5 (june 2014)
|
|
|
7.
|
|
6 p, 198.5 KB |
Lipid-lowering drugs in ischaemic heart disease : a quasi-experimental uncontrolled before-and-after study of the effectiveness of clinical practice guidelines
/
Dalmau, Rosa (Institut Universitari d'Investigació en Atenció Primària (Tortosa, Catalunya)) ;
Boira, Míriam (Institut Universitari d'Investigació en Atenció Primària. ABS Flix (Flix, Catalunya)) ;
Aguilar Martín, Carina (Institut Universitari d'Investigació en Atenció Primària (Tortosa, Catalunya)) ;
López, Carlos (Institut Universitari d'Investigació en Atenció Primària (Tortosa, Catalunya)) ;
Rodríguez, Dolores (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Gentille-Lorente, Delicia (Hospital de Tortosa Verge de la Cinta) ;
Bofill, Domingo (Hospital de Tortosa Verge de la Cinta) ;
Diogène Fadini, Eduard (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Pepió, Josep M. (Institut Universitari d'Investigació en Atenció Primària (Tortosa, Catalunya))
Background: Cardiovascular diseases(CVD), specifically ischaemic heart disease(IHD), are the main causes of death in industrialized countries. Statins are not usually prescribed in the most appropriate way. [...]
2011 - 10.1186/1471-2261-11-47
BMC Cardiovascular disorders, Vol. 11, N. 47 (August 2011) , p. 1-6
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
